This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.
Ages 5-17 years of age
Diagnosis of cerebral palsy and dystonia causing interference
Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
Parent/legal guardian is willing and able to provide informed permission/assent for the study
Previously or currently taking trihexyphenidyl
Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements
Children's Mercy Hospital Kansas City
Lead sponsor
University of Kansas Medical Center
Collaborator